- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Clinical Trials
Study: Arthritis drug co-developed by Lilly shows promise
November 12, 2010
IBJ Staff and Bloomberg NewsLilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications
for autoimmune diseases.
MoreEli Lilly will have to beat odds to meet drug-rollout goals
October 30, 2010
J.K. WallEli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per
year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs
in back-to-back years.
MoreLilly suspends clinical trials after diabetes treatment fails
October 20, 2010
Bloomberg NewsEli Lilly and Co. and its development partner said an experimental diabetes treatment failed to help patients in a late-stage
study, the second setback for a Lilly diabetes drug candidate in two days.
MoreUPDATE: Lilly, others see stock slide after drug rejection
October 20, 2010
Bloomberg NewsStock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in
a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
MoreQ&A
October 20, 2010
J.K. WallAmy Zucker is president of Indianapolis-based Synergy Marketing Group. Her firm was recently hired by Indianapolis-based ImmuneWorks Inc. to use a new website and search engine optimization to help recruit patients for a Phase 1 trial of ImmuneWorks experimental medicine idiopathic pulmonary fibrosis. The Web strategy is a new wrinkle on patient recruitment—in addition to the traditional partnerships with disease specialists at academic medical centers—that Zucker hopes leads to lower costs and faster clinical trials. Phase 1 clinical trials cost nearly $16,000 per patient.
FDA demands more tests on new Lilly diabetes drug
October 19, 2010
J.K. WallEli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly
version of diabetes drug Byetta, a potential billion-dollar drug.
MoreLilly's Erbitux shows mixed results in cancer studies
October 11, 2010
Bloomberg NewsIn combination with chemotherapy, the drug failed to help colon-cancer patients in a European trial but did delay the spread
of breast cancer in some patients with a certain type of aggressive tumor.
MorePearl IRB first firm in state to pre-screen clinical drug trials
August 21, 2010
Chris O'MalleyTwo former Eli Lilly and Co. employees launched the firm that promises to attract more clinical trial business to the state.
MoreLilly halts development of Alzheimer's drug
August 17, 2010
IBJ Staff and Associated PressStudies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
MoreDiagnostics division to help Lilly tailor treatments
July 10, 2010
J.K. WallEli Lilly and Co. is launching a diagnostics division to produce tests that can winnow out the patients most likely to benefit
from a Lilly drug.
MoreLilly, Amylin stock rises on drug postponement
June 18, 2010
IBJ Staff and Bloomberg NewsRoche Holding AG's decision to postpone its experimental diabetes drug is helping boost shares in Amylin Pharmaceuticals
Inc. and drug partner Eli Lilly and Co.
MoreLilly, GE announce cancer diagnostic breakthrough
October 21, 2009
J.K. WallEli Lilly and Co. and General Electric Co. say they've made a breakthrough in cancer research that could help Lilly cut the
size and cost of its clinical trials.
MoreEndocyte receives $26M infusion from investors
October 16, 2009
West Lafayette-based Endocyte Inc. announced Friday that it has closed on $26 million in equity financing to help the company
continue developing cancer-fighting drugs.
MoreAIT Laboratories leaps up Inc.'s list
August 24, 2009
IBJ StaffThe Indianapolis-based forensics, clinical and pharmaceutical testing firm now ranks 598, up from 1,466 a year ago. The list
is based on percentage of revenue growth.
MoreLilly's Effient launch just one of its many challenges
August 3, 2009
Greg AndrewsEli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials
take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
MoreLilly cancels trials for experimental MS drug
July 28, 2009
J.K. WallEli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
MoreIn spite of criticism, Lilly saves lives
March 30, 2009
Steven J.My wife, Becky, is alive today because of Lilly and its trial drug Enzastaurin, a great surgeon, and a terrific team of local
doctors.
MoreBiotech push may help offset generic competition; some analysts skeptical
February 2, 2009
J.K. WallLilly executives want to make biotech their top focus.
MoreOBS Medical hopes to capture pharma's heart
January 19, 2009
J.K. WallThe latest product to come out of Carmel-based OBS Medical may be just what the doctors ordered. The doctors working for major
pharmaceutical companies, that is.
MoreGeneric meds cost more than consumers realize
December 15, 2008
Generic drug makers drive up the cost of name-brand drugs developed by locally based Eli Lilly and Co. and other pharmaceutical
firms.
MoreLilly taps hedge fund to cut research costs for Alzheimer's drugs
August 11, 2008
J.K. WallEli Lilly and Co.'s unorthodox efforts to develop new treatments for Alzheimer's disease--if successful--could usher in a new approach to drug development. The Indianapolis-based pharmaceutical company announced that a New York hedge fund, TPG-Axon Capital, will invest up to $325 million to help cover the exorbitant development costs of two experimental compounds to treat Alzheimer's disease.
Lilly expects FDA approval of long-acting version of Zyprexa
February 4, 2008
J.K. WallEli Lilly and Co. hopes to extend the life of its best-seller Zyprexa with a potentially lucrative, long-acting form of the
antipsychotic drug. But first, the Indianapolis-based drugmaker must win over a panel of medical experts convened by the U.S.
Food and Drug Administration on Feb. 6.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Ameriana Bank took over Westfield Farmers Market for 2013 and it is held in their parking lot, corner of 32 and Carey road, 5 to 8. I am selling soap and candles there. great market!
B&T certainly has enough of our taxpayer dollars to do this thanks to Mayor Ballard. Given the firm's exceedingly poor reputation in the legal community, the basement would seem a better option.
Should read MAY hire 20 people.
Not a good location for a 300,000 home. 10th Street fumes, buses, noise. Max for this location 150,000.
The state constitution also does not say that the majority has a right to quorum, nor that the minority is required to allow them quorum. In fact, denial of quorum has been a parliamentary maneuver since the establishment of the first parliaments in the early 1600s. The right to deny quorum (and the requirement fore quorum) are to prevent exactly what happened in Indiana: A tyrannical majority pushing through odious, objectionable legislation. Denial of quorum is totally legitimate, and lest we forget, a tactic the GOP has employed many, many times to ensure their issues weren't given short shrift. By allowing the majority to impose "fines" on the minority for exercising the authority the constitution grants them (to deny quorum,) they are violating the constitution.